Wall Street analysts expect Vaccinex Inc (NASDAQ:VCNX) to announce earnings per share (EPS) of ($0.70) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Vaccinex’s earnings. The firm is expected to issue its next quarterly earnings results on Wednesday, August 21st.
According to Zacks, analysts expect that Vaccinex will report full-year earnings of ($2.35) per share for the current financial year, with EPS estimates ranging from ($2.48) to ($2.21). For the next financial year, analysts anticipate that the firm will report earnings of ($2.01) per share, with EPS estimates ranging from ($2.29) to ($1.73). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Vaccinex.
Vaccinex (NASDAQ:VCNX) last released its quarterly earnings data on Wednesday, May 15th. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.04). The business had revenue of $0.09 million for the quarter.
Separately, Zacks Investment Research upgraded Vaccinex from a “hold” rating to a “buy” rating and set a $8.75 target price for the company in a report on Thursday, May 16th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $17.58.
Several hedge funds have recently added to or reduced their stakes in the company. Telemetry Investments L.L.C. lifted its holdings in shares of Vaccinex by 26.3% in the fourth quarter. Telemetry Investments L.L.C. now owns 14,720 shares of the company’s stock valued at $54,000 after purchasing an additional 3,066 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Vaccinex during the third quarter worth approximately $124,000. Vanguard Group Inc. acquired a new stake in Vaccinex during the third quarter worth approximately $341,000. Finally, Vanguard Group Inc acquired a new stake in shares of Vaccinex in the 3rd quarter valued at $341,000. Institutional investors own 1.57% of the company’s stock.
NASDAQ:VCNX opened at $5.71 on Thursday. Vaccinex has a 52-week low of $3.32 and a 52-week high of $12.00. The firm has a market cap of $65.49 million and a PE ratio of -1.10.
Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.
Featured Article: Outstanding Shares, Buying and Selling Stocks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.